RxDoctor Payments Data

Carmin Kalorin, MD

Urology · Raleigh, NCNPI 1952559635

Payments from drug & device makers

$4,481in general payments, 2019–2025

Across 166 payments — averaging $26.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$491
  • Boston Scientific$389
  • Johnson & Johnson$301
  • Urogen Pharma, Inc.$258
  • Procept Biorobotics Corporation$191
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,03190%
  • Education$45010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,481 in reported general payments places this provider in the 60th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$158,870
Medicare patients
497
Services billed
2,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron166$120,584
GemtesaVibegron86$66,421
Tamsulosin Hcl680$12,297
Silodosin111$8,646
Finasteride438$6,998
Alfuzosin Hcl ErAlfuzosin Hcl162$4,459
Oxybutynin Chloride ErOxybutynin Chloride55$1,996
Testosterone Cypionate38$1,877
Testosterone12$1,586
Bicalutamide50$1,465
Solifenacin Succinate24$1,288
Oxybutynin Chloride40$871
Doxycycline Monohydrate52$840
Dutasteride16$792
Ciprofloxacin Hcl108$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,185$120,584166 claims
Sumitomo Pharma America, Inc.Gemtesa$491$66,42186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 434 urology providers in North Carolina.

Other urology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →